Bull
$195.33
Precio del escenario
$61.440
+0.627 (+1.02%)Al cierre
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.
Inspire Medical Systems Inc is a good buy right now due to its strong Q2 earnings performance, reporting a non-GAAP EPS of $0.14, which exceeded expectations by $0.39. Additionally, the company raised its 2026 revenue outlook to between $835 million and $875 million, indicating confidence in future growth. The current price of $61.44 is significantly below the analyst price target of $85, suggesting a potential upside of 38.3%. However, the forward P/E ratio is extremely high at 1111.11, indicating that the stock may be overvalued if growth does not materialize as expected.
Mizuho
$65
2026-08-04
Mizuho
2026-08-04
Precio objetivo
$65
JPMorgan
$60
2026-08-04
JPMorgan
2026-08-04
Precio objetivo
$60
Evercore ISI
$54
2026-08-04
Evercore ISI
2026-08-04
Precio objetivo
$54
BofA
$45
2026-08-04
BofA
2026-08-04
Precio objetivo
$45
Truist
$62
2026-08-04
Truist
2026-08-04
Precio objetivo
$62
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Inspire Medical Systems to Present at Wells Fargo Healthcare Conference

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Transcript

Inspire Medical Systems Reports Strong Q2 Performance and Upgrades Guidance

Inspire Medical Systems Q2 2026 Earnings Beat Expectations

Inspire Medical Systems Reports Return to Profitability in Q2
Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Inspire Medical Systems Inc is a good buy right now due to its strong Q2 earnings performance, reporting a non-GAAP EPS of $0.14, which exceeded expectations by $0.39. Additionally, the company raised its 2026 revenue outlook to between $835 million and $875 million, indicating confidence in future growth. The current price of $61.44 is significantly below the analyst price target of $85, suggesting a potential upside of 38.3%. However, the forward P/E ratio is extremely high at 1111.11, indicating that the stock may be overvalued if growth does not materialize as expected.
5 analysts cover INSP: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 145.31.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.